Exploring Semaglutide’s Impact on Knee Osteoarthritis and Weight

New findings from STEP 9 reveal significant pain and weight reduction benefits for OA patients.

Apr 24, 2024

∙ Paid

A realistic medical setting showing a doctor discussing treatment options with a patient. The doctor, a middle-aged Caucasian man, is pointing to a digital screen displaying a graph, symbolizing weight loss and pain reduction. The patient, a middle-aged African American woman, looks engaged and hopeful. They are in a modern consultation room with medical charts and a model of a knee joint on the desk. The atmosphere is professional and supportive, with no visible text or numbers.

Topline:

Recent results from the STEP 9 study highlight the potential of semaglutide, a GLP-1 receptor agonist, to facilitate significant weight loss and reduce knee pain in obese patients with knee osteoarthritis, marking a promising advancement in treatment options.

Study Details:

The STEP 9 study, discussed at the World Congress on Osteoarthritis 2024…

Keep reading with a 7-day free trial

Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.